Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

IMDX

STRONG SELL

Insight Molecular Diagnostics Inc. · Healthcare · United States · $153M · Avg Vol: $1M/d

7
StockRank
Get insider-trade alerts
Q
16
V
23
M
38
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
Dir. Trades · 180d
None →
Buybacks · 180d
None →
Loading 1Y...
PRICE (1Y)-16.2%
4.464.825.185.545.90Jun 12Jul 7Jul 27
SMA 50SMA 200
Close
$4.70
RSI (14)
44.5
52W High
$8.51
From 52W High
0.6%

SCORE BREAKDOWN

Quality
16
ROIC
-348.9%1.1
ROE
—N/A
GP/Assets
3.9%17.8
Op. Margin
-32275.0%1.1
FCF/Assets
-106.7%1.4
Piotroski
239.0
Int. Cover
-50.0x6.3
D/E Ratio
—N/A
Current Ratio
2.54x47.5
Value
23
P/E (TTM)
—N/A
EV/EBITDA
-3.9x25.0
P/FCF
—N/A
P/B
-14.3x25.0
P/S
78.5x8.6
Div Yield
—N/A
Momentum
38
52W High %
55%32.9
RS 6M
-36%25.3
SMA 50/200
1.01x67.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+48%53.7
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$153M
P/E (Forward)
-6.1x
Gross Margin
51.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMDX are excluded.

TickerCompanyMkt CapStockRankSignal
IMDXInsight Molecular Diagnostics Inc.(you)$153M7STRONG SELL
XGNExagen Inc.$113M17STRONG SELL
950130.KQAccess Bio, Inc.$60M9STRONG SELL
BDSXBiodesix, Inc.$228M38HOLD
CSTLCastle Biosciences, Inc.$749M19STRONG SELL
FRNMFreenome, Inc.$1.2B11STRONG SELL
FLGTFulgent Genetics, Inc.$559M27SELL
MYGNMyriad Genetics, Inc.$530M35SELL
WGSGeneDx Holdings Corp.$1.8B14STRONG SELL
PSNLPersonalis, Inc.$1.3B24SELL

Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%

Insight Molecular Diagnostics Inc. (IMDX) — Stock Score Summary

Insight Molecular Diagnostics Inc. (IMDX) has a MoatMap StockRank of 7/100 based on Quality (16/100), Value (23/100), and Momentum (38/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price$4.70
Market Cap$153M
P/E (Forward)-6.08
Price/Book-14.32
Return on Invested Capital-348.9%
Gross Margin51.1%
Operating Margin-32275.0%
Revenue Growth-98.5%
Free Cash Flow$-27M

Insight Molecular Diagnostics Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Insight Molecular Diagnostics Inc.’s (IMDX) StockRank?
MoatMap’s StockRank for Insight Molecular Diagnostics Inc. (IMDX) is 7/100, with a Strong Sell signal. It is a composite of Quality (16), Value (23), and Momentum (38) factor ranks across MoatMap’s 20,000+ stock universe.
Does Insight Molecular Diagnostics Inc. have an economic moat?
Insight Molecular Diagnostics Inc. (IMDX) has a Quality factor score of 16/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Insight Molecular Diagnostics Inc. a buy, hold, or sell?
MoatMap’s current signal for Insight Molecular Diagnostics Inc. (IMDX) is Strong Sell, based on a StockRank of 7/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Insight Molecular Diagnostics Inc. in?
Insight Molecular Diagnostics Inc. (IMDX) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).
Browse all ranked stocksIMDX deep dive reportAI ChampionsHow we score stocksSense-check another stock